Christoph Nowak

Chief Tech/Sci/R&D Officer presso DIAMYD MEDICAL AB

Patrimonio netto: 585 $ in data 31/03/2024

38 anni

Consumer Services

Health Technology

Profilo

Christoph Nowak is currently an Independent Director at OncoZenge AB, a Chief Medical & Business Officer at Diamyd Medical AB, and a Chief Medical Officer at Melius Pharma AB.
Previously, he worked as an Assistant Professor at Karolinska Institutet.
He holds a doctorate degree from the University of Oxford, the University of Uppsala, and Technische Universität Braunschweig.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
DIAMYD MEDICAL AB CLASS B 0.00%	31/08/2023	597 ( 0.00% )	585 $	31/03/2024

Posizioni attive di Christoph Nowak

Società	Posizione	Inizio
DIAMYD MEDICAL AB	Chief Tech/Sci/R&D Officer	-
ONCOZENGE AB	Director/Board Member	09/09/2023
Melius Pharma AB Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients.	Chief Tech/Sci/R&D Officer	-

Tutte le posizioni attive di Christoph Nowak

Precedenti posizioni note di Christoph Nowak

Società	Posizione	Fine
Karolinska Institutet	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Christoph Nowak

Formazione di Christoph Nowak

University of Oxford	Doctorate Degree
University of Uppsala	Doctorate Degree
Technische Universität Braunschweig	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Christoph Nowak

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
DIAMYD MEDICAL AB	Health Technology
ONCOZENGE AB	Health Technology

Aziende private	1
Melius Pharma AB Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients.	Health Technology